Theriva Biologics Inc (TOVX)

$0.47 -0.01 (-2.63%)
Market Cap 3.93M
Revenue (ttm) 0.00
Net Income (ttm) -25.65M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.10
Volume 180,500
Avg Vol 1,731,564
Day's Range N/A - N/A
Shares Out 8.19M
Stochastic %K 44%
Beta 0.85
Analysts Hold
Price Target $7.00

Company Profile

Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company's lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma, ovarian cancer, colorect...

Industry: Biotechnology
Sector: Healthcare
Phone: 301 417 4364
Address:
9605 Medical Center Drive, Suite 270, Rockville, United States
HectorNumba9
HectorNumba9 Jun. 16 at 6:48 PM
$TOVX just keep blocking the noobs in here
0 · Reply
neily51
neily51 Jun. 16 at 3:13 PM
$TOVX scam syn tovx syn .
0 · Reply
dogood
dogood Jun. 16 at 2:18 PM
$TOVX worst management , once she breaks .45 heading to .20 for reversal splits
0 · Reply
dogood
dogood Jun. 16 at 11:35 AM
$TOVX can you run today
0 · Reply
Juststocks_77
Juststocks_77 Jun. 16 at 12:46 AM
$TOVX : Had a reverse split in August 2024. Is it going to happen again???
1 · Reply
Nakuldesai
Nakuldesai Jun. 13 at 7:10 PM
$TOVX i think this is going to 30c
0 · Reply
Capone78
Capone78 Jun. 13 at 5:37 PM
$TOVX drowning in 💩
0 · Reply
dogood
dogood Jun. 13 at 9:11 AM
$TOVX long waiting to get $3 today ?
0 · Reply
Abrahmalincolnbrother
Abrahmalincolnbrother Jun. 13 at 12:09 AM
$TOVX Tomorrow is the day $KLTO
0 · Reply
dogood
dogood Jun. 12 at 10:32 PM
$TOVX I dreamed she opens at $1.3 today morning , but nothing
0 · Reply
Latest News on TOVX
Theriva™ Biologics Reports First Quarter 2025 Operational Highlights and Financial Results

May 14, 2025, 8:40 AM EDT - 4 weeks ago

Theriva™ Biologics Reports First Quarter 2025 Operational Highlights and Financial Results

Theriva Biologics Announces Closing of $7.5 Million Public Offering

May 8, 2025, 4:30 PM EDT - 5 weeks ago

Theriva Biologics Announces Closing of $7.5 Million Public Offering

Theriva Biologics Announces Pricing of $7.5 Million Public Offering

May 7, 2025, 9:17 AM EDT - 5 weeks ago

Theriva Biologics Announces Pricing of $7.5 Million Public Offering

Theriva Biologics Announces Presentation of Data from the Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients

Apr 10, 2025, 8:00 AM EDT - 2 months ago

Theriva Biologics Announces Presentation of Data from the Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients

Theriva™ Biologics to Present at the 2025 NeauxCancer Conference

Mar 19, 2025, 8:10 AM EDT - 3 months ago

Theriva™ Biologics to Present at the 2025 NeauxCancer Conference

Theriva™ Biologics Reports Full-Year 2024 Operational Highlights and Financial Results

Mar 6, 2025, 4:10 PM EST - 3 months ago

Theriva™ Biologics Reports Full-Year 2024 Operational Highlights and Financial Results

Theriva™ Biologics to Participate in the Q1 Investor Summit Virtual

Mar 5, 2025, 4:05 PM EST - 3 months ago

Theriva™ Biologics to Participate in the Q1 Investor Summit Virtual

Theriva™ Biologics Announces U.S. FDA Guidance on Design of Phase 3 Study of VCN-01 for the Treatment of Metastatic Pancreatic Cancer

Dec 5, 2024, 8:00 AM EST - 6 months ago

Theriva™ Biologics Announces U.S. FDA Guidance on Design of Phase 3 Study of VCN-01 for the Treatment of Metastatic Pancreatic Cancer

Theriva Biologics Announces Orphan Medicinal Product Designation Granted by the European Commission to VCN-01 for the Treatment of Retinoblastoma

Oct 16, 2024, 8:00 AM EDT - 8 months ago

Theriva Biologics Announces Orphan Medicinal Product Designation Granted by the European Commission to VCN-01 for the Treatment of Retinoblastoma

Theriva Biologics Announces Pricing of $2.5 Million Public Offering

Sep 26, 2024, 9:06 PM EDT - 9 months ago

Theriva Biologics Announces Pricing of $2.5 Million Public Offering

Theriva™ Biologics Achieves Target Patient Enrollment in the VIRAGE Phase 2b Trial of VCN-01 with Gemcitabine/nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer

Sep 23, 2024, 8:00 AM EDT - 9 months ago

Theriva™ Biologics Achieves Target Patient Enrollment in the VIRAGE Phase 2b Trial of VCN-01 with Gemcitabine/nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer

Theriva™ Biologics Awarded Manufacturing Funding from the Spanish Government's National Knowledge Transfer Program

Sep 16, 2024, 8:00 AM EDT - 9 months ago

Theriva™ Biologics Awarded Manufacturing Funding from the Spanish Government's National Knowledge Transfer Program

Theriva Biologics Announces Reverse Stock Split

Aug 16, 2024, 4:05 PM EDT - 10 months ago

Theriva Biologics Announces Reverse Stock Split

Theriva™ Biologics Receives Rare Pediatric Drug Designation by the U.S. FDA for VCN-01 for the Treatment of Retinoblastoma

Jul 31, 2024, 8:15 AM EDT - 11 months ago

Theriva™ Biologics Receives Rare Pediatric Drug Designation by the U.S. FDA for VCN-01 for the Treatment of Retinoblastoma

Theriva™ Biologics Announces Fast Track Designation Granted by the U.S. FDA for VCN-01 for the Treatment of Metastatic Pancreatic Cancer

May 23, 2024, 8:15 AM EDT - 1 year ago

Theriva™ Biologics Announces Fast Track Designation Granted by the U.S. FDA for VCN-01 for the Treatment of Metastatic Pancreatic Cancer

Theriva™ Biologics to Participate in the A.G.P. Virtual Healthcare Conference

May 14, 2024, 8:00 AM EDT - 1 year ago

Theriva™ Biologics to Participate in the A.G.P. Virtual Healthcare Conference

Theriva™ Biologics Reports First Quarter 2024 Operational Highlights and Financial Results

May 7, 2024, 7:00 AM EDT - 1 year ago

Theriva™ Biologics Reports First Quarter 2024 Operational Highlights and Financial Results

Theriva™ Biologics to Discuss the Trial Design for VIRAGE - a Phase 2b Clinical Study of Systemically Administered VCN-01 in Combination with Chemotherapy in Pancreatic Ductal Adenocarcinoma - at the 2024 American Society of Clinical Oncology (ASCO) Annua

Apr 25, 2024, 8:15 AM EDT - 1 year ago

Theriva™ Biologics to Discuss the Trial Design for VIRAGE - a Phase 2b Clinical Study of Systemically Administered VCN-01 in Combination with Chemotherapy in Pancreatic Ductal Adenocarcinoma - at the 2024 American Society of Clinical Oncology (ASCO) Annua

Theriva™ Biologics Announces Positive Topline Data from Investigator Sponsored Phase 1 Trial of Intravitreal VCN-01 in Pediatric Patients with Refractory Retinoblastoma

Apr 23, 2024, 7:00 AM EDT - 1 year ago

Theriva™ Biologics Announces Positive Topline Data from Investigator Sponsored Phase 1 Trial of Intravitreal VCN-01 in Pediatric Patients with Refractory Retinoblastoma

Theriva™ Biologics to Present Preclinical Data Supporting the Potential Synergy of VCN-01 and First-Line Pancreatic Cancer Chemotherapy Regimens at the American Society for Cell and Gene Therapy 27th Annual Meeting

Apr 22, 2024, 4:35 PM EDT - 1 year ago

Theriva™ Biologics to Present Preclinical Data Supporting the Potential Synergy of VCN-01 and First-Line Pancreatic Cancer Chemotherapy Regimens at the American Society for Cell and Gene Therapy 27th Annual Meeting

Theriva™ Biologics Announces Presentation at the American Society for Cell and Gene Therapy 27th Annual Meeting

Apr 8, 2024, 8:00 AM EDT - 1 year ago

Theriva™ Biologics Announces Presentation at the American Society for Cell and Gene Therapy 27th Annual Meeting

Theriva Biologics, Inc. (TOVX) Q4 2023 Earnings Call Transcript

Mar 25, 2024, 12:01 PM EDT - 1 year ago

Theriva Biologics, Inc. (TOVX) Q4 2023 Earnings Call Transcript

Theriva™ Biologics Reports Full-Year 2023 Operational Highlights and Financial Results

Mar 25, 2024, 7:30 AM EDT - 1 year ago

Theriva™ Biologics Reports Full-Year 2023 Operational Highlights and Financial Results

Theriva™ Biologics to Host Conference Call and Webcast to Discuss Full Year 2023 Operational Highlights and Financial Results

Mar 19, 2024, 8:00 AM EDT - 1 year ago

Theriva™ Biologics to Host Conference Call and Webcast to Discuss Full Year 2023 Operational Highlights and Financial Results

Theriva™ Biologics to Participate in the BIO-Europe Spring Conference

Mar 11, 2024, 8:00 AM EDT - 1 year ago

Theriva™ Biologics to Participate in the BIO-Europe Spring Conference

Theriva Biologics Announces Positive Recommendation from the Independent Data Monitoring Committee of VIRAGE, the Phase 2b Clinical Trial of VCN-01 in Combination with Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma

Feb 7, 2024, 8:00 AM EST - 1 year ago

Theriva Biologics Announces Positive Recommendation from the Independent Data Monitoring Committee of VIRAGE, the Phase 2b Clinical Trial of VCN-01 in Combination with Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma

Theriva Biologics to Participate in the B. Riley Securities Annual Oncology Conference

Jan 16, 2024, 8:00 AM EST - 1 year ago

Theriva Biologics to Participate in the B. Riley Securities Annual Oncology Conference

Theriva Biologics, Inc. (TOVX) Q3 2023 Earnings Call Transcript

Nov 17, 2023, 12:51 PM EST - 1 year ago

Theriva Biologics, Inc. (TOVX) Q3 2023 Earnings Call Transcript

Theriva™ Biologics Reports Third Quarter 2023 Operational Highlights and Financial Results

Nov 13, 2023, 8:00 AM EST - 1 year ago

Theriva™ Biologics Reports Third Quarter 2023 Operational Highlights and Financial Results

Theriva Biologics to Host Conference Call and Webcast to Discuss Third Quarter 2023 Operational Highlights and Financial Results

Nov 6, 2023, 4:05 PM EST - 1 year ago

Theriva Biologics to Host Conference Call and Webcast to Discuss Third Quarter 2023 Operational Highlights and Financial Results

Theriva™ Biologics to Participate in the BIO-Europe Conference

Nov 2, 2023, 4:15 PM EDT - 1 year ago

Theriva™ Biologics to Participate in the BIO-Europe Conference

Theriva™ Biologics and Sant Joan de Déu-Barcelona Children's Hospital Advance Strategic Collaboration to Explore the Combination of VCN-01 with Topoisomerase Inhibitors to Treat Cancer

Nov 2, 2023, 8:00 AM EDT - 1 year ago

Theriva™ Biologics and Sant Joan de Déu-Barcelona Children's Hospital Advance Strategic Collaboration to Explore the Combination of VCN-01 with Topoisomerase Inhibitors to Treat Cancer

Theriva™ Biologics Presents Survival Outcomes Data from Phase 1 Study Evaluating VCN-01 in Combination with Durvalumab in Patients with Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck at ESMO Congress 2023

Oct 23, 2023, 7:00 AM EDT - 1 year ago

Theriva™ Biologics Presents Survival Outcomes Data from Phase 1 Study Evaluating VCN-01 in Combination with Durvalumab in Patients with Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck at ESMO Congress 2023

Theriva™ Biologics Announces Presentation at ESMO Congress 2023 Featuring Survival Outcomes in Phase 1 Study Evaluating VCN-01 in Combination with Durvalumab in Patients with Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Oct 16, 2023, 8:00 AM EDT - 1 year ago

Theriva™ Biologics Announces Presentation at ESMO Congress 2023 Featuring Survival Outcomes in Phase 1 Study Evaluating VCN-01 in Combination with Durvalumab in Patients with Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Theriva Biologics to Participate in the Emerging Growth Conference

Sep 28, 2023, 8:00 AM EDT - 1 year ago

Theriva Biologics to Participate in the Emerging Growth Conference

Theriva Biologics, Inc. (TOVX) Q2 2023 Earnings Call Transcript

Aug 12, 2023, 1:52 PM EDT - 2 years ago

Theriva Biologics, Inc. (TOVX) Q2 2023 Earnings Call Transcript

Theriva™ Biologics Reports Second Quarter 2023 Operational Highlights and Financial Results

Aug 8, 2023, 8:00 AM EDT - 2 years ago

Theriva™ Biologics Reports Second Quarter 2023 Operational Highlights and Financial Results

Theriva™ Biologics Announces Key Progress in VIRAGE, an Ongoing, Multinational Phase 2b Trial of VCN-01 in Combination with Chemotherapy in Pancreatic Ductal Adenocarcinoma

Aug 2, 2023, 7:00 AM EDT - 2 years ago

Theriva™ Biologics Announces Key Progress in VIRAGE, an Ongoing, Multinational Phase 2b Trial of VCN-01 in Combination with Chemotherapy in Pancreatic Ductal Adenocarcinoma

Theriva Biologics to Host Conference Call and Webcast to Discuss Second Quarter 2023 Operational Highlights and Financial Results

Aug 1, 2023, 4:05 PM EDT - 2 years ago

Theriva Biologics to Host Conference Call and Webcast to Discuss Second Quarter 2023 Operational Highlights and Financial Results

Theriva Biologics Announces Orphan Drug Designation Granted by the U.S. FDA for VCN-01 for the Treatment of Pancreatic Cancer

Jun 27, 2023, 4:10 PM EDT - 2 years ago

Theriva Biologics Announces Orphan Drug Designation Granted by the U.S. FDA for VCN-01 for the Treatment of Pancreatic Cancer

Theriva Biologics Announces Appointment of Ramon Alemany, Ph.D., to Senior Vice President of Discovery

May 23, 2023, 8:00 AM EDT - 2 years ago

Theriva Biologics Announces Appointment of Ramon Alemany, Ph.D., to Senior Vice President of Discovery

Theriva Biologics Reports First Quarter 2023 Operational Highlights and Financial Results

May 11, 2023, 8:00 AM EDT - 2 years ago

Theriva Biologics Reports First Quarter 2023 Operational Highlights and Financial Results

Theriva Biologics to Host Conference Call and Webcast to Discuss First Quarter 2023 Operational Highlights and Financial Results

May 4, 2023, 8:00 AM EDT - 2 years ago

Theriva Biologics to Host Conference Call and Webcast to Discuss First Quarter 2023 Operational Highlights and Financial Results

Theriva Biologics Announces Presentation of Data from Cohort 1 of the Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients

Apr 13, 2023, 8:00 AM EDT - 2 years ago

Theriva Biologics Announces Presentation of Data from Cohort 1 of the Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients

Theriva Biologics Reports Fourth Quarter and Full-Year 2022 Operational Highlights and Financial Results

Mar 30, 2023, 8:00 AM EDT - 2 years ago

Theriva Biologics Reports Fourth Quarter and Full-Year 2022 Operational Highlights and Financial Results

Theriva Biologics to Reschedule Conference Call and Webcast to Discuss Fourth Quarter and Full-Year 2022 Operational Highlights and Financial Results

Mar 24, 2023, 4:05 PM EDT - 2 years ago

Theriva Biologics to Reschedule Conference Call and Webcast to Discuss Fourth Quarter and Full-Year 2022 Operational Highlights and Financial Results

Theriva Biologics to Host Conference Call and Webcast to Discuss Fourth Quarter and Full-Year 2022 Operational Highlights and Financial Results

Mar 20, 2023, 8:00 AM EDT - 2 years ago

Theriva Biologics to Host Conference Call and Webcast to Discuss Fourth Quarter and Full-Year 2022 Operational Highlights and Financial Results

Theriva Biologics Announces Presentation of Safety and Pharmacokinetic Data from Cohort 1 of the Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients

Feb 16, 2023, 12:05 PM EST - 2 years ago

Theriva Biologics Announces Presentation of Safety and Pharmacokinetic Data from Cohort 1 of the Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients

Theriva Biologics to Participate in the B. Riley Securities 3rd Annual Oncology Conference

Jan 17, 2023, 4:05 PM EST - 2 years ago

Theriva Biologics to Participate in the B. Riley Securities 3rd Annual Oncology Conference

Theriva Biologics Announces First Patient Dosed in VIRAGE, a Phase 2b Trial of Systemically Administered VCN-01 in Combination with Chemotherapy in Pancreatic Ductal Adenocarcinoma

Jan 17, 2023, 8:00 AM EST - 2 years ago

Theriva Biologics Announces First Patient Dosed in VIRAGE, a Phase 2b Trial of Systemically Administered VCN-01 in Combination with Chemotherapy in Pancreatic Ductal Adenocarcinoma

HectorNumba9
HectorNumba9 Jun. 16 at 6:48 PM
$TOVX just keep blocking the noobs in here
0 · Reply
neily51
neily51 Jun. 16 at 3:13 PM
$TOVX scam syn tovx syn .
0 · Reply
dogood
dogood Jun. 16 at 2:18 PM
$TOVX worst management , once she breaks .45 heading to .20 for reversal splits
0 · Reply
dogood
dogood Jun. 16 at 11:35 AM
$TOVX can you run today
0 · Reply
Juststocks_77
Juststocks_77 Jun. 16 at 12:46 AM
$TOVX : Had a reverse split in August 2024. Is it going to happen again???
1 · Reply
Nakuldesai
Nakuldesai Jun. 13 at 7:10 PM
$TOVX i think this is going to 30c
0 · Reply
Capone78
Capone78 Jun. 13 at 5:37 PM
$TOVX drowning in 💩
0 · Reply
dogood
dogood Jun. 13 at 9:11 AM
$TOVX long waiting to get $3 today ?
0 · Reply
Abrahmalincolnbrother
Abrahmalincolnbrother Jun. 13 at 12:09 AM
$TOVX Tomorrow is the day $KLTO
0 · Reply
dogood
dogood Jun. 12 at 10:32 PM
$TOVX I dreamed she opens at $1.3 today morning , but nothing
0 · Reply
Nakuldesai
Nakuldesai Jun. 12 at 5:39 PM
$TOVX hope you all sold in 50s. This is going more lower. Shorts can do rug pull at any given time.
0 · Reply
HectorNumba9
HectorNumba9 Jun. 12 at 2:44 PM
$TOVX idiots wanna be $PLRZ
0 · Reply
ABBA888
ABBA888 Jun. 12 at 1:55 PM
$TOVX I’m still here you sons of bees
0 · Reply
Nakuldesai
Nakuldesai Jun. 12 at 1:49 PM
$TOVX There come the rug pull back to the 40s
0 · Reply
HectorNumba9
HectorNumba9 Jun. 11 at 9:24 PM
$TOVX u idiots if this pumps i bought enough to get my $$ back n leave yall in the dust. Rather the cheap buyout less shallcross has something up sleeve. And its coming whatever it is
0 · Reply
Oreos62
Oreos62 Jun. 11 at 9:14 PM
$TOVX nah its not manipulation
0 · Reply
karku
karku Jun. 11 at 8:55 PM
$TOVX no no no no.. I want also the .49xx shares :) easy PM 20-30%
0 · Reply
Abrahmalincolnbrother
Abrahmalincolnbrother Jun. 11 at 7:49 PM
$USAU Watch $TOVX run AH %200 Runner
0 · Reply
RollingDollars
RollingDollars Jun. 11 at 6:32 PM
$TOVX
0 · Reply
RollingDollars
RollingDollars Jun. 11 at 6:32 PM
$TOVX .
0 · Reply
Nakuldesai
Nakuldesai Jun. 11 at 6:31 PM
$TOVX bids are not moving up. if this has to move bids also need to move.
0 · Reply
JAG_2_Trade
JAG_2_Trade Jun. 11 at 5:25 PM
$TOVX no any news for over 2 weeks, bit this is heading up. PUMP and DUMP??? Be careful guys.
1 · Reply